Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)

Most Recent Videos

$11B Wiped From Greek Banks on Nationalization Threat
20:08 - Jan. 28 -- Bloomberg’s Trish Regan reports on today's top stories on “Street Smart.”
  • Boston Responding to 6th Largest Blizzard Ever: Mayor
  • Can the Fed Really Afford to Stay Patient on Rates?
  • Admissions Racket: Why Are Colleges Extending Deadlines?